Presentations
GTB-3550 TriKE™ - Target Directed Serial Killing of AML Cancer Cell by NK Cells
GTB-3550 ASH 2020 Meeting Supplement Presentation – Treatment of HR-MDS Patient
GTB-3550 Clinical Trial Interim Results: Erica Warlick, M.D., Principal Investigator. American Society of Hematology (ASH) meeting, December 5, 2020.
Corporate Presentation
GT Biopharma Interview with Proactive Investors at the 11th Annual Biotech Showcase in San Francisco
- « Previous '; ?>
- 1
- 2